Mounjaro London 2026 Complete Guide to Tirzepatide Weight Loss Injections
Medically reviewed by The Online GP by The Wellness clinical team
Last updated April 2026
Mounjaro tirzepatide is the most effective licensed weight loss injection currently available in the UK, producing 15 to 22.5 percent average body weight loss over 72 weeks of treatment. It is a once-weekly injection that works on two appetite-regulating hormones GLP-1 and GIP, making it more powerful than single-hormone medications like Wegovy or Saxenda.
Private Mounjaro treatment in London ranges from £120 to £375 per month depending on the provider, with substantial differences in clinical care quality between the cheapest online pharmacy services and proper doctor-led programmes.
At The Online GP by The Wellness in Marylebone, doctor-led Mounjaro treatment costs £225 to £275 per month inclusive of medication, prescription, and structured clinical monitoring, with full GMC-registered medical assessment before initiation.
This guide explains exactly how Mounjaro works, who is eligible, what results to expect, how it compares with Wegovy and other options, and why proper clinical supervision matters more than the lowest headline price. Tirzepatide is a powerful medication with real side effects and requires structured medical care to use safely and effectively.
Speak to a GMC-registered doctor today
WhatsApp +44 7961 280835
Email team@thewellnesslondon.com
Call 020 3951 3429
What is Mounjaro and how does it work?
Mounjaro is the brand name for tirzepatide, a once-weekly subcutaneous injection manufactured by Eli Lilly. It is licensed by the MHRA in the UK for both type 2 diabetes treatment and chronic weight management in adults. The active mechanism is dual receptor agonism — tirzepatide activates both GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptors, the two major incretin hormone pathways involved in appetite, satiety, blood glucose regulation, and gastric emptying.
The dual-receptor mechanism is what makes Mounjaro fundamentally different from earlier GLP-1 medications. Wegovy, Ozempic, and Saxenda all activate GLP-1 only. Mounjaro activates both pathways, producing additive effects on appetite suppression, fullness, slower stomach emptying, and improved glucose control. The result is the highest average weight loss of any currently available licensed weight loss medication.
In practical terms, Mounjaro reduces hunger, increases satiety after smaller meals, slows the rate at which food leaves your stomach, and reduces the cognitive preoccupation with food that drives overeating in many patients with obesity. The medication does not magically burn fat. It changes the biological signalling that drives caloric intake, making it substantially easier to eat less without constant willpower depletion.
Treatment is delivered via a pre-filled KwikPen that contains 4 weekly doses. Each dose is a single subcutaneous injection into the abdomen, thigh, or upper arm, typically taken at the same time each week. Dose escalation begins at 2.5mg weekly for the first 4 weeks, then increases by 2.5mg every 4 weeks based on tolerability and response, up to a maintenance dose of 5mg, 7.5mg, 10mg, 12.5mg, or 15mg. Most patients reach their effective dose within 16 to 20 weeks.
How effective is Mounjaro for weight loss?
Mounjaro produces the highest average weight loss of any currently available licensed weight loss medication, with 15 to 22.5 percent body weight reduction over 72 weeks of treatment in clinical trials.
The pivotal SURMOUNT-1 trial (Jastreboff et al., July 2022) randomised 2,539 participants without diabetes to tirzepatide or placebo and demonstrated 20.9 percent average body weight loss at the 15mg maintenance dose, 19.5 percent at 10mg, and 15 percent at 5mg, compared with 3.1 percent in the placebo group.
For context, that represents approximately:
20kg loss in a person starting at 100kg on the 15mg dose
17.5kg loss in a person starting at 90kg on the 10mg dose
12kg loss in a person starting at 80kg on the 5mg dose
Comparative effectiveness against other licensed weight loss medications:
Mounjaro (tirzepatide) — GLP-1 + GIP dual agonist — 15 to 22.5% average weight loss (72 weeks, SURMOUNT-1)
Wegovy (semaglutide 2.4mg) — GLP-1 agonist — 15 to 17% average weight loss (68 weeks, STEP-1)
Ozempic (semaglutide 1mg, off-label) — GLP-1 agonist — 6 to 13% average weight loss
Saxenda (liraglutide 3mg) — GLP-1 agonist — 5 to 8% average weight loss
Orlistat (Xenical) — Fat absorption blocker — 3 to 6% average weight loss
Real-world results vary substantially. Around 70 to 80 percent of patients respond well to Mounjaro with at least 10 percent weight loss within 6 months. Around 15 to 20 percent are partial responders with 5 to 10 percent loss. A small minority (5 to 10 percent) are non-responders, typically requiring evaluation of dose, adherence, lifestyle factors, or alternative treatment.
Beyond pure weight reduction, Mounjaro produces other measurable health benefits:
HbA1c reduction of approximately 1.8 to 2.4 percent in patients with type 2 diabetes
Blood pressure reduction averaging 6 to 8 mmHg systolic
Triglyceride reduction of approximately 25 percent
Liver fat reduction of approximately 30 percent (relevant to non-alcoholic fatty liver disease)
Sleep apnoea improvement in patients with co-existing OSA
These metabolic improvements, combined with weight loss, translate into reduced cardiovascular risk and lower likelihood of progressing from prediabetes to type 2 diabetes.
Want a personalised assessment of likely results? WhatsApp +44 7961 280835 for same-day reply
Am I eligible for Mounjaro?
MHRA licensing for weight management with Mounjaro requires BMI of 30 or above, or BMI of 27 to 30 with at least one weight-related health condition. NICE guidance for NHS access is more restrictive (typically BMI 35 with conditions, via specialist services only). Private clinics typically prescribe within the MHRA licensed criteria. Some clinics extend prescribing from BMI 25 where benefits outweigh risks and the patient has substantial weight-related health concerns, though this is off-label and requires careful clinical justification.
Weight-related health conditions that support eligibility at BMI 27 to 30:
High blood pressure (hypertension)
Type 2 diabetes or prediabetes
Sleep apnoea (obstructive sleep apnoea)
Cardiovascular disease (heart attack, stroke, heart failure)
Dyslipidaemia (high cholesterol or triglycerides)
Non-alcoholic fatty liver disease (NAFLD)
Polycystic ovary syndrome (PCOS) with metabolic features
Osteoarthritis affecting weight-bearing joints
Absolute contraindications — Mounjaro is not safe to prescribe regardless of weight:
Personal or family history of medullary thyroid carcinoma (MTC)
Multiple endocrine neoplasia syndrome type 2 (MEN-2)
Hypersensitivity to tirzepatide or any excipient
Pregnancy or active attempt to conceive
Breastfeeding
Relative contraindications require careful assessment and may rule out treatment:
History of pancreatitis
Severe gastrointestinal disease including gastroparesis
Diabetic retinopathy with recent worsening
Severe kidney impairment (CKD stage 4 to 5)
Severe liver disease
Active eating disorder including bulimia nervosa
History of suicidal ideation or active mental health crisis
Type 1 diabetes (Mounjaro is licensed for type 2 only)
Specific medication interactions require dose review:
Oral contraceptive pills may have reduced effectiveness during dose escalation
Insulin and sulphonylureas require dose adjustment when combined with Mounjaro
Warfarin requires INR monitoring after starting
The eligibility assessment at The Wellness is a structured 30-minute consultation including detailed medical history, medication review, BMI confirmation, blood pressure measurement, and baseline blood tests covering HbA1c, kidney function, liver function, lipid profile, thyroid function, and amylase or lipase. This pre-treatment assessment identifies any contraindications and establishes baseline values for monitoring.
How does Mounjaro compare with Wegovy and Ozempic?
Mounjaro, Wegovy, and Ozempic are all weekly injectable medications affecting the GLP-1 system, but they differ in mechanism, efficacy, indication, and cost. Choosing between them depends on your specific clinical picture, prior medication experience, side effect tolerance, and budget.
Mounjaro (tirzepatide) — GLP-1 + GIP dual agonist — Licensed for weight loss and type 2 diabetes in UK — 15 to 22.5% average weight loss — Maximum dose 15mg weekly — Typical UK private cost £225 to £375/month
Wegovy (semaglutide 2.4mg) — GLP-1 agonist — Licensed for weight loss in UK — 15 to 17% average weight loss — Maximum dose 2.4mg weekly — Typical UK private cost £169 to £309/month
Ozempic (semaglutide 1mg) — GLP-1 agonist — Licensed for type 2 diabetes only (off-label for weight loss) — 6 to 13% average weight loss — Maximum dose 1mg weekly — Supply constrained, priority for diabetes patients
When Mounjaro is typically the right choice:
Highest weight loss target (over 15 percent of body weight)
Co-existing type 2 diabetes (Mounjaro is licensed for both indications)
Wegovy non-responders or partial responders
Patients who can tolerate gastrointestinal side effects
Budget allows £225 monthly investment
When Wegovy is typically the right choice:
Slightly lower weight loss target (10 to 15 percent)
Better tolerability for GI side effects in some patients
Longer post-launch safety data preference
Slightly lower cost
When Ozempic is typically the right choice:
Type 2 diabetes is the primary indication and weight loss is secondary
Mounjaro is unsuitable due to side effects
Note: Ozempic is not licensed for weight loss and prescribing it for that purpose is off-label
Other options to be aware of:
Saxenda (liraglutide) — daily injection, lower efficacy (5 to 8 percent), mostly superseded by weekly options
Orlistat (Xenical, Alli) — oral medication blocking fat absorption, much lower efficacy (3 to 6 percent)
Compounded semaglutide or tirzepatide — not licensed in the UK. The MHRA has issued warnings about unlicensed compounded GLP-1 from non-UK sources.
Need help choosing the right medication? WhatsApp +44 7961 280835 for a structured consultation
How much does Mounjaro cost in London?
Mounjaro costs in London 2026 range from £120 to £375 per month depending on the provider, dose, and what is included in the headline price. The London market includes:
Online-only pharmacies at the budget end — £120 to £180/month, medication only with minimal clinical input
Mid-market doctor-led services — £200 to £300/month, medication plus consultation and monitoring
Premium clinic services — £300 to £400/month, comprehensive specialist care
The Wellness Mounjaro pricing (verified April 2026):
Step 1: Initial Specialist Consultation (30 min) — £150
Step 2: Baseline Blood Test Panel (HbA1c, kidney, liver, lipids, thyroid) — £295
Step 3: First month medication (2.5mg dose, KwikPen with 4 weekly doses) — £225
Step 4: Follow-up consultation at 1 month — £150
Step 5: Ongoing medication and monthly review — £225 to £275/month
Optional: Subscription package (3, 6, or 12 month plans) — Discounted pricing
Typical first-year cost at The Wellness: approximately £3,200 to £3,800 total covering initial consultation, baseline testing, monthly medication and reviews, and one annual review with comprehensive blood retesting.
Why proper clinical supervision matters more than the lowest price:
Mounjaro is a powerful medication with measurable serious side-effect risk. The cheapest online pharmacy services typically charge £120 to £180 per month for medication only, with minimal clinical input, no examination, no baseline blood tests, no in-person follow-up, and limited communication for side effects.
The mid-market doctor-led approach we operate at The Wellness charges more because it includes:
Initial 30-minute consultation with GMC-registered doctor reviewing full medical history
Baseline blood tests including HbA1c, kidney function, liver function, lipid profile, and thyroid screen
Monthly clinical review during dose escalation phase, then 3-monthly during maintenance
Direct WhatsApp access to your treating clinician for side effects or questions
Side effect management including anti-emetic prescriptions where needed
Annual comprehensive assessment including repeat blood work
Continuity with the same doctor across your treatment
Comparison with London competitors (verified April 2026):
Mayfair Weight Loss Clinic — Mounjaro from £210/month, online consultation model
London Slimming Clinic — From £210/month, online platform
Phlo Clinic — From £149 first pen, £169/month after, postal delivery model
Bolt Pharmacy — £150 to £250/month, online questionnaire model
Joinvoy.com — Subscription model with bundle discounts, doctor-led
NHS list price — approximately £293/month
Premium private GP services with GLP-1 — £275 to £375/month with full clinical care
The Wellness sits at the doctor-led mid-premium position: full clinical care without the consultant-fee markup of weight management physician practices.
Get a personalised pricing quote — WhatsApp +44 7961 280835
What are the side effects of Mounjaro?
Mounjaro side effects are predominantly gastrointestinal and predominantly occur during dose escalation phases. Most settle within 4 to 8 weeks as your body adapts to the medication. Serious side effects are rare but require awareness and prompt response.
Very common side effects (more than 10 percent of patients):
Nausea (20 to 25 percent) — typically worst in first 1 to 2 weeks of each new dose, settling over 3 to 4 weeks. Anti-emetics (ondansetron, metoclopramide) can be prescribed where troublesome.
Diarrhoea (15 to 20 percent) — typically self-limiting, may require dose pause or temporary reduction.
Constipation (10 to 15 percent) — paradoxically common because gastric emptying slows. Hydration and gentle laxatives where needed.
Decreased appetite (universal) — this is the intended therapeutic effect, but can be problematic if it leads to inadequate nutrition.
Vomiting (10 percent) — persistent vomiting requires dose review.
Common side effects (1 to 10 percent of patients):
Indigestion and reflux
Abdominal pain and bloating
Fatigue, particularly in first few weeks
Headache
Dizziness on standing (orthostatic hypotension)
Hypoglycaemia in patients on insulin or sulphonylureas
Injection site reactions (redness, mild swelling)
Hair thinning (typically in patients losing weight rapidly)
Loss of muscle mass alongside fat (mitigated by adequate protein intake and resistance exercise)
Serious but uncommon side effects (under 1 percent):
Pancreatitis — severe persistent abdominal pain, sometimes radiating to the back, with nausea and vomiting. Requires immediate cessation of Mounjaro and emergency assessment.
Gallbladder disease — rapid weight loss is a known risk factor for gallstones. Right upper abdominal pain warrants assessment.
Acute kidney injury — usually secondary to dehydration from severe gastrointestinal symptoms. Adequate hydration during titration is essential.
Diabetic retinopathy worsening in patients with pre-existing diabetic eye disease.
Severe hypoglycaemia in patients on insulin or sulphonylureas without dose adjustment.
Allergic reactions — from local skin reactions to rare systemic anaphylaxis.
Black box warning: Tirzepatide caused thyroid C-cell tumours in rodent studies. Whether this risk translates to humans is uncertain. Mounjaro is contraindicated in personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.
Mental health considerations: Some patients on GLP-1 medications report mood changes including anxiety or low mood. Causation versus association is debated. The MHRA monitors this signal closely. Pre-existing mental health conditions are not contraindications but warrant careful monitoring.
Side effect management at The Wellness includes:
Pre-emptive anti-nausea medication available on prescription where indicated
Dose pause or reduction if side effects are intolerable, with structured re-escalation
Direct WhatsApp access to your clinician for guidance during side effect episodes
Annual blood work to detect any biochemical changes early
Specialist referral if complex side effects develop
Most patients tolerate Mounjaro well after the first 4 to 8 weeks. Around 5 to 10 percent of patients discontinue because of intolerable side effects.
What does the Mounjaro pathway look like at The Wellness?
The Mounjaro pathway at The Online GP by The Wellness is structured around proper clinical care. Six stages cover initial assessment, treatment initiation, dose titration, maintenance, ongoing review, and long-term planning.
Stage 1: Initial consultation — £150, 30 minutes. Your GMC-registered doctor takes a detailed history covering weight history, prior weight loss attempts, medical conditions, medications, family history, mental health, eating patterns, and goals. Examination includes BMI calculation, blood pressure, basic cardiovascular assessment.
Stage 2: Baseline assessment — £295. Blood tests covering HbA1c, full kidney function, liver function, lipid profile, thyroid function, amylase and lipase, full blood count, vitamin D, and any other tests indicated by your history. Results typically within 24 to 48 hours.
Stage 3: Treatment initiation — £225 first month medication. Once eligibility is confirmed, you receive a private prescription for Mounjaro 2.5mg KwikPen (4 weeks of starting dose). We provide injection technique training including video demonstration, written instructions, and supplies.
Stage 4: Dose escalation phase — months 1 to 5. Monthly follow-up consultations during titration to assess response, side effects, weight progress, and any issues. Dose increases by 2.5mg every 4 weeks based on tolerability. Most patients reach their effective maintenance dose between 5mg and 15mg over 16 to 20 weeks.
Stage 5: Maintenance phase — months 6 onwards. Once stable on your maintenance dose, reviews move to every 3 months. Weight loss typically continues for 12 to 18 months from start before plateauing. Annual comprehensive blood retest assesses metabolic improvement.
Stage 6: Long-term planning — year 2 onwards. After reaching target weight, decisions about continuation, dose reduction, or transition off medication are made based on individual factors. Most patients benefit from ongoing maintenance treatment because stopping typically results in weight regain.
What is included throughout:
All consultations during dose titration and maintenance
Direct WhatsApp access to your treating clinician for side effects and questions
Prescription writing and partner pharmacy dispensing
Weight tracking and review at each appointment
Annual blood work review
Diet and lifestyle guidance integrated into consultations
Side effect management including supportive prescriptions
Specialist referral pathways if needed
Begin your Mounjaro pathway — WhatsApp +44 7961 280835
Email team@thewellnesslondon.com
Why choose The Wellness for Mounjaro in London?
The Online GP by The Wellness offers a deliberately structured Mounjaro pathway designed around clinical safety, transparent pricing, and continuity of care. Six elements distinguish our approach from the online-pharmacy model dominating the budget end of the market.
GMC-registered doctors with substantive consultation time. Every patient is seen by a doctor for a full 30-minute initial consultation, not assessed via a 10-minute online questionnaire. This identifies contraindications and tailors the approach to your specific situation. BMA and GMC guidance recommend in-person or video consultation with examination for weight loss medication initiation.
Marylebone clinic with full diagnostic capability. 10 Portman Square sits two minutes from Baker Street and adjacent to Harley Street. Baseline blood tests, blood pressure monitoring, and clinical examination all happen at the same location, in the same visit.
Same-day appointment availability. Most patients book their initial consultation within 1 to 3 days. Pathway from first contact to first dose is typically 1 to 5 days — much faster than NHS specialist weight management services (6 to 18 month waits) and competitive with online services without sacrificing clinical depth.
Multilingual care. GMC-registered doctors fluent in English, Arabic, Spanish, French, and Dutch, supporting our substantial international patient base from the Middle East, Europe, and the Americas.
Continuity of care. You see the same doctor throughout your pathway. WhatsApp access between appointments. Clinical record retained securely for the full duration of treatment.
MHRA-compliant prescribing. We prescribe within MHRA licensed indications and monitor according to BMA, GMC, and Royal College of Physicians guidance. We do not offer compounded semaglutide or tirzepatide, which is unlicensed in the UK and warned against by MHRA.
This is a genuinely premium-but-accessible private weight management service — full clinical care for £225 to £275 per month, equivalent in quality to consultant-led practices charging £350 but without the consultant-fee markup.
Frequently asked questions
Will my private medical insurance cover Mounjaro?
Most UK private medical insurance policies do not cover weight loss medication including Mounjaro, treating it as a lifestyle medication rather than treatment for a disease. However, some policies cover diagnostic consultations and baseline blood tests under investigation of new or worsening symptoms — particularly where weight is contributing to other conditions like type 2 diabetes, hypertension, or sleep apnoea. Check specific coverage with your insurer before booking. We provide itemised invoices to support claims.
Can I switch to Mounjaro from Wegovy or Ozempic?
Yes. Patients on Wegovy or Ozempic can switch to Mounjaro after specialist assessment, often starting at a higher Mounjaro dose if they are stable on a high semaglutide dose. The transition typically involves stopping the previous GLP-1, waiting 7 to 14 days, then starting Mounjaro at an appropriate dose. We assess each patient individually to determine the safest starting dose.
Do I need to follow a specific diet on Mounjaro?
Not a specific diet, but adequate protein intake (1 to 1.5g per kg of body weight) is important to preserve muscle mass during rapid weight loss. Hydration is essential to reduce gastrointestinal side effects and prevent kidney issues. Resistance exercise (2 to 3 times weekly) helps maintain muscle mass. Most patients naturally eat substantially less due to appetite suppression, so the focus shifts from eating less to eating well within smaller portions.
Can Mounjaro affect my contraception?
Yes. Mounjaro can reduce the effectiveness of oral contraceptive pills, particularly during dose escalation phases due to slowed gastric emptying affecting absorption. We recommend additional contraception (barrier methods, IUD, implant, or injectable contraception) for the first 4 weeks after starting Mounjaro and for 4 weeks after each dose increase. This is important because Mounjaro is contraindicated in pregnancy. Discuss your contraception during your consultation.
Can I drink alcohol on Mounjaro?
Moderate alcohol consumption is not strictly contraindicated, but several considerations matter. Mounjaro slows gastric emptying, which can amplify alcohol effects and produce nausea. Hypoglycaemia risk increases with alcohol in patients on Mounjaro plus other diabetes medications. Many patients naturally find alcohol less appealing due to early satiety and the medication's effect on reward pathways. Total weekly intake should remain within UK guidelines (14 units), with alcohol-free days recommended.
What happens when I stop Mounjaro?
Stopping Mounjaro typically results in gradual weight regain over 12 to 18 months because the underlying biology of appetite regulation returns to baseline. Studies show approximately two-thirds of weight loss is regained within 12 months of stopping. This is why Mounjaro is increasingly viewed as a long-term treatment for chronic weight management, similar to how blood pressure medication is taken long-term. Some patients can transition to lower maintenance doses for ongoing benefit at lower cost.
Is Mounjaro safe long-term?
Currently available data extends to 3 to 5 years for tirzepatide and longer for related GLP-1 medications. Long-term safety data is reassuring overall, with the main concerns being thyroid C-cell tumour risk (theoretical, based on rodent studies, not yet seen in human population data), pancreatitis risk (rare but real), and gallbladder issues related to rapid weight loss. Ongoing post-market surveillance through the MHRA Yellow Card scheme tracks any emerging signals. We monitor patients with annual blood work and clinical review.
Book your Mounjaro consultation today
Mounjaro is the most effective weight loss medication currently licensed in the UK. With proper clinical care, around 70 to 80 percent of patients lose 10 percent or more of their body weight within 6 months, and 20 to 30 percent achieve 20 percent or more loss over 12 to 18 months. The results are real, the side effects are manageable for most, and the medication is now a mainstream tool in private weight management.
The Online GP by The Wellness offers same-day initial consultations at our Marylebone clinic and via secure video, with GMC-registered doctors, full integrated diagnostics, transparent monthly pricing, and continuity of care through your treatment journey. We do not prescribe Mounjaro from online questionnaires alone, in line with BMA and GMC guidance.
Three ways to book today:
WhatsApp +44 7961 280835 for a same-day reply from our medical team
Email team@thewellnesslondon.com for detailed enquiries, insurance questions, or international patient queries
Phone 020 3951 3429 to speak directly to our team during clinic hours
The Wellness, 10 Portman Square, Marylebone, London W1H 6AZ. GMC-registered doctors. Same-day appointments. Doctor-led Mounjaro care from £225/month. The right way to do weight loss medicine.
References and further reading:
Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine, July 2022
Eli Lilly Mounjaro KwikPen Summary of Product Characteristics, MHRA
NICE Technology Appraisal TA1026 — Tirzepatide for managing overweight and obesity
NICE Technology Appraisal TA875 — Semaglutide for managing overweight and obesity
MHRA guidance on unlicensed compounded weight loss medications
British Medical Association guidance on private prescribing of weight loss medications
Royal College of Physicians position on obesity as a chronic disease
Disclaimer: This article is for educational purposes only and does not constitute medical advice. Mounjaro is a prescription-only medication requiring individual medical assessment before initiation. Side effects can be significant and require appropriate clinical management. Pregnancy must be avoided during treatment. The Wellness is a private healthcare clinic with GMC-registered doctors. We prescribe within MHRA licensed indications and monitor according to BMA and GMC guidance.
